SELLAS Life Sciences Group Inc SLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLS is a good fit for your portfolio.
News
-
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
-
Sellas Life Sciences Gets Favorable Meeting Feedback From FDA
-
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)
-
SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
-
SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
-
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Sellas Life Sciences Shares Rise 7.6% on Fast Track Designation for Cancer Treatment by FDA
-
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.04–1.11
- 52-Week Range
- $0.81–4.13
- Bid/Ask
- $1.07 / $1.08
- Market Cap
- $34.63 Mil
- Volume/Avg
- 479,605 / 593,153
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
Valuation
|
Metric
|
SLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SLS
Financial Strength
|
Metric
|
SLS
|
|---|---|
Quick Ratio | 0.34 |
Current Ratio | 0.44 |
Interest Coverage | — |
Quick Ratio
SLS
Profitability
|
Metric
|
SLS
|
|---|---|
Return on Assets (Normalized) | −177.47% |
Return on Equity (Normalized) | −576.19% |
Return on Invested Capital (Normalized) | −517.28% |
Return on Assets
SLS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mmr | $456.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wqcblh | $91.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vsgfxrk | $89.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Fzxsfb | $40.2 Bil | |
MRNA
| Moderna Inc | Rtgn | $29.6 Bil | |
ARGX
| argenx SE ADR | Bhp | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Klpz | $23.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Splljm | $21.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rwtnff | $17.2 Bil | |
INCY
| Incyte Corp | Xzgvxg | $12.2 Bil |